During the earnings conference call the ceo said one of the main causes of lawsuits against PTCT is from patients seeking to be included in their clinical trials. If patient interest is any indicator, that is a good thing.
SRPT is not a competitor and the consensus in the field was that their clinical trial did not have the proper marker for measuring success. On the other hand PTCT has had measurable success w/o adverse events.
Look for positive news early in Q1 2014.
Q3 earnings beat on top & bottom line. 3 firms increased px tgt this week to $34.50 and $35 respectively and one firm initiated with a $26 tgt. decline has been low volume and Europe EMA meeting by year end to review DMD conditional approval in Q1 '14. No analyst has #'s factored in for this early potential approval. Stock is a screaming buy here.
First of all, nobody knows about this stock, Several presentations and R&D analyst day have done little to raise the profile. All you need to look at imo is the insider participation in the ipo and their eating a whole bunch of their own cooking. They have personal skin in the game and Celgene owns a 5% stake. Prior to the ipo they sold several 5% stakes to companies that have since been taken over. That coupled with a free ride with Roche study of their spinal muscular atrophy that costs them nothing makes this story compelling.
A gift under $20 imo.